Business Context and Reporting Period
This Form 8-K, dated August 3, 2026, reports a material event for Lantheus Holdings, Inc. (LNTH). The filing announces the execution of an Agreement and Plan of Merger with Curium US Holdings LLC (Parent) and Coco Merger Sub Inc. The transaction involves the proposed acquisition of Lantheus by Parent. Concurrently, the Company announced it is pausing its previously disclosed CEO search process.
Key Financial Metrics
This filing is a Current Report regarding a corporate transaction and does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. Investors are directed to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent filings for financial data.
Material Changes
- Merger Agreement: Execution of a definitive agreement for Curium US Holdings LLC to acquire Lantheus Holdings, Inc.
- Leadership Search: Immediate pause of the ongoing CEO search process due to the proposed acquisition.
- Regulatory Filings: The Company intends to file a preliminary and definitive proxy statement to solicit stockholder approval for the transaction.
Outlook, Risks, and Contingencies
Transaction Conditions: The merger is subject to customary closing conditions, including stockholder approval, regulatory approvals, and the satisfaction of other conditions outlined in the Merger Agreement.
Contingent Value Rights (CVRs): The transaction includes CVRs tied to specific milestones. Risks include uncertainty regarding whether these milestones will be achieved and if payments will be made to CVR holders.
Operational and Regulatory Risks:
- Product Approvals: Risks associated with obtaining final FDA approval for PNT2003 (tentatively approved March 2026) and LNTH-2501.
- Commercialization: Challenges in technology transfer for PYLARIFY TruVu across the PET manufacturing facility network, securing coding/coverage, and customer adoption.
- Integration: Risks related to integrating recent acquisitions (Lantheus Biosciences Ltd. and Evergreen Theragnostics) and potential disruption to business operations during the pendency of the merger.
- Competition and Litigation: Potential for competing offers, stockholder litigation, and patent litigation regarding PNT2003.
Investor Verification Checklist
- Review the Definitive Proxy Statement (to be filed) for full details on the merger terms, valuation, and voting procedures.
- Verify the status of regulatory approvals required to consummate the transaction.
- Monitor the CEO search status and potential leadership changes post-transaction.
- Assess the likelihood of achieving CVR milestones and the associated payout structure.
- Confirm the timeline for technology transfer and FDA approvals for PYLARIFY TruVu and PNT2003.